Risk Analysis for Second Hip Fracture in Patients After Hip Fracture Surgery: A Nationwide Population-Based Study

Shih Hsun Shen, Kuo Chin Huang*, Yao Hung Tsai, Tien Yu Yang, Mel S. Lee, Steve W.N. Ueng, Robert W.W. Hsu

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

46 Scopus citations

Abstract

Objectives: The current treatment program for fragility hip fractures (HFx) emphasizes a combination of early surgery, rehabilitation, and tertiary prevention strategy for osteoporosis; however, the effect is unclear and little information is available on the risk factors predicting the occurrence of a second hip fracture (SHFx). The aim of this study was to explore the incidence, risk factors, and subsequent mortality of SHFx in patients after their first hip fracture surgery (HFxS). Design, Setting, and Participants: We performed a nationwide population-based longitudinal observational study using the National Health Insurance Research Database (NHIRD) of Taiwan with a logistic regression model analysis. Of 87,415 patients undergoing HFxS during the period 2004 to 2007, we identified 8027 patients who had sustained an SHFx for analyses. Measurements: Data collected included patient characteristics (demographics, comorbidities, and concurrent medication use), incidence and hazard ratios of SHFx after HFxS, and subsequent age-specific mortality. Results: The overall incidence of SHFx was 9.18% and the age-specific mortality was increased 1.6- to 2.2-fold in patients with SHFx compared with those without after HFxS in this 7-year longitudinal study. The identified risk factors included age (AOR= 1.84, 95% CI: 1.24-2.89), female gender (AOR= 1.12, 95% CI: 1.03-2.30), obesity (AOR= 2.89, 95% CI: 1.81-3.01), diabetes (AOR= 3.85, 95% CI: 2.54-4.05), arterial hypertension (AOR= 2.45, 95% CI: 1.83-2.62), hyperlipidemia (AOR= 2.77, 95% CI: 1.27-3.19), stroke/TIA (AOR= 2.85, 95% CI: 2.20-3.23), blindness/low vision (AOR= 3.09, 95% CI: 2.54-3.73), and prolonged use of analgesics and anti-inflammatory medications (all AOR ≥ 3.05, all P values ≤.012). Bisphosphonate therapy after HFxS had a significant negative risk association with the development of an SHFx (20.8% vs 32.3%, P= .023; AOR= 2.24, 95% CI: 1.38-2.90). Conclusion: We concluded that the occurrence of an SHFx and subsequent mortality in patients after HFxS is rather high. An understanding of the risk factors predicting the occurrence of an SHFx provides a valuable basis to improve health care for geriatric populations.

Original languageEnglish
Pages (from-to)725-731
Number of pages7
JournalJournal of the American Medical Directors Association
Volume15
Issue number10
DOIs
StatePublished - 2014

Bibliographical note

Publisher Copyright:
© 2014 AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Keywords

  • Fracture risk
  • Geriatrics
  • Mortality
  • Osteoporosis
  • Population-based study
  • Second hip fracture

Fingerprint

Dive into the research topics of 'Risk Analysis for Second Hip Fracture in Patients After Hip Fracture Surgery: A Nationwide Population-Based Study'. Together they form a unique fingerprint.

Cite this